ATC Group: N05AL05 Amisulpride

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N05AL05 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N05 Psycholeptics
3 N05A Antipsychotics
4 N05AL Benzamides
5 N05AL05 Amisulpride

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.4 g

Active ingredients in N05AL05

Active Ingredient Description
Amisulpride

Amisulpride is a neuroleptic. Amisulpride binds selectively with a high affinity to human dopaminergic D2/D3 receptor subtypes whereas it is devoid of affinity for D1, D4 and D5 receptor subtypes.

Related product monographs

Title Information Source Document Type  
SOLIAN Tablets Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

Australia (AU)

Austria (AT)

Brazil (BR)

Croatia (HR)

Cyprus (CY)

Estonia (EE)

France (FR)

Germany (DE)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Italy (IT)

Lithuania (LT)

Malta (MT)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.